Live Breaking News & Updates on Combination With Hypomethylating Agents

Stay updated with breaking news from Combination with hypomethylating agents. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novartis Pharma AG: New data at ASH spotlight Novartis recently approved Scemblix, next-generation CAR-T platform and expanding hematology portfolio

New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies ....

United States , Isabella Zinck , Thomas Hungerbuehler , Susanne Schaffert , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Promacta Revolade , Alina Levchuk , Drug Administration , Incyte Corporation As Jakafi , Novartis Us External Communications , Novartis External Communications , Exchange Commission , American Society Of Hematology , Novartis Hematology Communications , Incyte Corporation , American Society , Annual Meeting , First In Human Study , Charge Platform , Diffuse Largeb Cell Lymphoma , Fully Human , Refractory Multiple Myeloma Manufactured , Malignant Hematology ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

Investegate announcements from NOVARTIS AG CHF0.50(REGD), New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio ....

United States , Isabella Zinck , Thomas Hungerbuehler , Susanne Schaffert , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Promacta Revolade , Alina Levchuk , Drug Administration , Incyte Corporation As Jakafi , Novartis Us External Communications , Novartis External Communications , Exchange Commission , American Society Of Hematology , Novartis Hematology Communications , Incyte Corporation , American Society , Annual Meeting , First In Human Study , Diffuse Largeb Cell Lymphoma , Fully Human , Refractory Multiple Myeloma Manufactured , Malignant Hematology , Combination With Hypomethylating Agents ,